Tradestie Institutional Equity Comparison Engine

CADL vs EVMN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CADL Overall Edge

CADL Captures Institutional Edge (2โ€“2 Pillars ยท 5โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Candel Therapeutics, Inc. Common Stock (CADL) driven by superior Valuation, Momentum & Technical while EVMN counters with relative strength in Growth & Margin, Options & Structure. Fundamentally, CADL trades at 43.5x Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus EVMN at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CADL sits in BREAKDOWN (24th %ile IV; Dealer Gamma Walls on Pro) against EVMN sits in SURGE (53rd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CADL
CADL 43.5x vs EVMN N/M Fwd P/E
Growth & Margin Winner EVMN
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner CADL
1Y +26.0% vs -61.0% ยท 52W Pos 15% vs 8%
Options & Structure Winner EVMN
BREAKDOWN (24th %ile IV) vs SURGE (53rd %ile IV)
CADL NASDAQ
Candel Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$5.81
-6.29% 1D
Market Cap $486.4M
1M Return -29.06%
1Y Return +26.03%
Forward P/E 43.5x
Unified AI Score
46.0 / 100 HOLD
Tech 33.0 Fund 55.0 Flow 70.0 Mom 64.0
EVMN US Equity
Evommune, Inc.
Pharmaceutical Preparations
$7.10
-6.95% 1D
Market Cap $315.5M
1M Return +37.33%
1Y Return -61.03%
Forward P/E N/M
Unified AI Score
30.0 / 100 SELL
Tech 50.0 Fund 35.0 Flow 69.0 Mom 44.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CADL +26.03% EVMN -61.03% Spread: +87.06 pp (CADL Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CADL Revenue EVMN Revenue CADL Op. Margin EVMN Op. Margin Margin Edge
FY2020 $0M N/A -11048.0% N/A CADL
FY2021 $0M N/A -20580.8% N/A CADL
FY2022 $0M N/A -27777.6% N/A CADL
FY2024 N/A $10M N/A -1000.2% EVMN
FY2025 N/A $10M N/A -623.6% EVMN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CADL (5) vs EVMN (2)
Institutional Metric CADL EVMN Criterion Row Winner
Market Capitalization Scale $486.4M $315.5M Larger Scale CADL
Trailing P/E Ratio Valuation 43.5x N/M Lower Multiple CADL
Forward P/E Ratio Valuation 43.5x N/M Lower Multiple CADL
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -93.7% -69.5% Higher ROE EVMN
52-Week Range Position Momentum 15% ($4โ€“$14) 8% ($5โ€“$33) Stronger Trend CADL
Beta / 30D Volatility Risk Regime 2.12ฮฒ ยท 125% Vol 1.05ฮฒ ยท 118% Vol Lower Realized Risk EVMN
Unified Institutional Score Composite Signal 46.0 / 100 (HOLD) 30.0 / 100 (SELL) Higher Composite CADL

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CADL vs EVMN Buy Guide
CADL BREAKDOWN
98d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 24th %ile
IV Regime Compressed (<25th %ile)
Live CADL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
EVMN SURGE
5d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 53rd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live EVMN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CADL nor EVMN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.